Northwire Canada EditionWednesday, July 15, 2026
Northwire
SGQ 0.400 +5.3% GMX 1.87 −1.6% ALM 0.310 +0.0% WCU 0.010 +0.0% NTH 0.155 −6.1% GGM 0.035 +0.0% FG 0.035 +0.0% EFR 17.76 −4.5% IVN 10.54 −2.3% MASS 0.090 +0.0% LIF 26.61 −2.2% CPAU 0.155 +0.0% PTX 0.105 −4.5% VENT 0.160 +0.0% ANK 0.275 −5.2% ODV 3.34 −0.9% SGQ 0.400 +5.3% GMX 1.87 −1.6% ALM 0.310 +0.0% WCU 0.010 +0.0% NTH 0.155 −6.1% GGM 0.035 +0.0% FG 0.035 +0.0% EFR 17.76 −4.5% IVN 10.54 −2.3% MASS 0.090 +0.0% LIF 26.61 −2.2% CPAU 0.155 +0.0% PTX 0.105 −4.5% VENT 0.160 +0.0% ANK 0.275 −5.2% ODV 3.34 −0.9%

← Back to our analysis

Original News Release

Tempramed Technologies releases VIVI Med

Mr. Ron Nagar reports TEMPRAMED LAUNCHES NEW PRODUCT "VIVI MED," UNLOCKING NEW GROWTH OPPORTUNITIES IN HIGH-VALUE BIOLOGICS AND INJECTABLE MEDICATIONS Tempramed Technologies Ltd. has launched commercially VIVI Med, a new temperature-protection solution designed to safeguard medication vials, biologics and other critical therapies that fall outside the insulin-pen format. The launch of VIVI Med provides significant expansion of the company's total addressable market opportunity, by extending its proven thermal-protection technology into new drug categories, broader patient populations and higher-value use cases. By addressing medications such as GLP-1 receptor agonists, biologics including Humira, insulin vials, injectable medication vials and temperature-sensitive blood glucose test strips, VIVI Med substantially increases the scope of the company's commercial reach. As the global use of biologics, GLP-1 therapies and specialty injectables continues to grow across chronic, autoimmune and metabolic conditions, the need for reliable, portable and power-free temperature protection is becoming increasingly critical. VIVI Med is engineered to provide 24/7/365 passive protection for years -- without batteries, charging or maintenance-supporting real-world use across travel, work and active lifestyles. "To date, our product portfolio has focused on insulin pens and epinephrine auto-injectors, but the medication landscape is evolving rapidly," said Ron Nagar, chief executive officer of Tempramed. "VIVI Med is a strategic expansion of our platform that allows us to address a much broader universe of temperature-sensitive medications, many of which are high-value biologics with growing patient populations. This product materially expands our addressable market and creates new opportunities across consumer, B2B and health-care-system channels. Using our proprietary, patented technology, we will continue to expand our product portfolio with new products, new applications and new markets." Key features of VIVI Med Expanded compatibility: designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors and temperature- and light-sensitive glucose test strips; Year-round temperature protection: Maintains safe medication temperatures without refrigeration, electricity or maintenance; Portable and lifestyle-friendly: compact, lightweight, reusable design for daily use, travel and outdoor environments Durable, long-life construction: built with space-grade materials and engineered for years of repeated use. Strategic and commercial significance With the introduction of VIVI Med, Tempramed now offers a multiformat temperature-protection platform spanning: VIVI Cap and VIVI Cap Smart for insulin pens and certain GLP-1 pens; VIVI Epi for epinephrine auto-injectors; VIVI Med for vials, biologics, GLP-1 pens, test strips and broader injectable formats. About Tempramed Technologies Ltd. Tempramed Technologies is a global leader in innovative, temperature-controlled medication storage solutions. We seek Safe Harbor.
View at source ↗